microbeПроблемы особо опасных инфекцийProblems of Particularly Dangerous Infections0370-10692658-719XRussian Research Anti-Plague Institute “Microbe”10.21055/0370-1069-2015-3-98-103microbe-254Research ArticleБИОТЕХНОЛОГИЯ, ИММУНОЛОГИЯBIOTECHNOLOGY, IMMUNOLOGYСовременное состояние разработки средств экстренной профилактики и лечения болезни, вызванной вирусом ЭболаCurrent State of the Development of Therapies for Emergency Prophylaxis and Treatment of Ebola Virus DiseaseПетровА. А.PetrovA. A.noemail@neicon.ruЛебедевВ. Н.LebedevV. N.noemail@neicon.ruПлехановаТ. М.PlekhanovaT. M.noemail@neicon.ruСтовбаЛ. Ф.StovbaL. F.noemail@neicon.ruБорисевичГ. В.BorisevichG. V.noemail@neicon.ruСидороваО. Н.SidorovaO. N.noemail@neicon.ruЧухраляО. В.ChukhralyaO. V.noemail@neicon.ruБорисевичС. В.BorisevichS. V.noemail@neicon.ru48 Центральный научно-исследовательский институт Министерства обороныРоссияThe 48th Central Research Institute of the RF Ministry of DefenseRussian Federation2015200920150398103Copyright © Петров А.А., Лебедев В.Н., Плеханова Т.М., Стовба Л.Ф., Борисевич Г.В., Сидорова О.Н., Чухраля О.В., Борисевич С.В., 20152015Петров А.А., Лебедев В.Н., Плеханова Т.М., Стовба Л.Ф., Борисевич Г.В., Сидорова О.Н., Чухраля О.В., Борисевич С.В.Petrov A.A., Lebedev V.N., Plekhanova T.M., Stovba L.F., Borisevich G.V., Sidorova O.N., Chukhralya O.V., Borisevich S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.microbe.ru/jour/article/view/254

В качестве основных эффективных и экономичных мер борьбы с распространением эпидемии Эбола в настоящее время рассматривают вакцинацию населения в эндемичных регионах и внедрение в широкую клиническую практику эффективных средств экстренной профилактики и лечения. Целью настоящего обзора является анализ современного состояния разработки средств экстренной профилактики и лечения болезни, вызванной вирусом Эбола (БВВЭ). Основными направлениями создания эффективных средств экстренной профилактики и лечения лихорадки Эбола является разработка препаратов, основанных на вирусспецифических антителах (в том числе и моноклональных), малых интерферирующих РНК, антисмысловых фосфордиамидатных морфолиновых олигомерах и интерферонах. В обзоре рассмотрены наиболее значимые результаты в области создания средств экстренной профилактики и лечения БВВЭ.

Nowadays vaccination of the population living in the endemic regions and widespread implementation of the potent therapies for the emergency prophylaxis and treatment into the clinical practice are regarded as the basic efficient and cost-effective measures for Ebola epidemic spread control. Objective of the review is to analyze current state of the development of aids for the immediate prophylaxis and treatment of Ebola fever. Focus area of the activities is the construction of drugs on the basis of virus-specific anti-bodies (including monoclonal), small interfering RNA, and anti-sense phosphordiamidate morpholine oligomers and interferons. The paper discusses the most significant achievements in this sphere.

вирус Эболалекарственные средстваэкстренная профилактика и лечениевирусспецифические антителамоноклональные антителамалые интерферирующие РНКантисмысловые фосфордиамидатные морфолиновые олигомерыEbola virushemorrhagic fevermedical productsemergency prophylaxis and treatmentvirus-specific antibodiesmonoclonal antibodiessmall interfering RNAanti-sense phosphordiamidate morpholine oligomersReferencesBackground document potential Ebola therapies and vaccines. WHO, 3 September 2014.Background document potential Ebola therapies and vaccines. WHO, 3 September 2014.Basler C.F., Miculasova A., Martinez-Sobrido L., Paragas J., Muhlberger E., Bray M., Klenks H.D., Palese P., Garcia-Sastre A. The Ebola virus VP 35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003; 77:7945-56.Basler C.F., Miculasova A., Martinez-Sobrido L., Paragas J., Muhlberger E., Bray M., Klenks H.D., Palese P., Garcia-Sastre A. The Ebola virus VP 35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003; 77:7945–56.Burton D.R. Antibodies, viruses and vaccines. Nature Rev. Immunol. 2002; 2:706-13.Burton D.R. Antibodies, viruses and vaccines. Nature Rev. Immunol. 2002; 2:706–13.Choi J.H., Croyle V.A. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs. 2013; 27(6):565-83. DOI: 10.1007/540259-013-0046-1.Choi J.H., Croyle V.A. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs. 2013; 27(6):565–83. DOI: 10.1007/540259-013-0046-1.CNN News. Available from: http://edition.cnn.com./2014/08/21/health/ebola-pacient-release/index.html (дата обращения 22.08.2014).CNN News. 21 Aug 2014 [cited 22 Aug 2014]. Available from: http://edition.cnn.com./2014/08/21/health/ebola-pacient-release/index.html.Davidson B.L., McCray Jr. P.B. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011; 12:329-40.Davidson B.L., McCray Jr P.B. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011; 12:329–40.De Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: A progress report on siРНК-based therapeutics. Nat. Rev. Drug Discov. 2007; 6:443-53.De Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: A progress report on siРНК -based therapeutics. Nat. Rev. Drug Discov. 2007; 6:443–53.Ebihara H., Takada A., Kobasa D., Jones S., Neumann G., Therian H.S., Bray M., Feldmann H., KawaokaY. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2006; 2: e73.Ebihara H., Takada A., Kobasa D., Jones S., Neumann G., Therian H.S., Bray M., Feldmann H., KawaokaY. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2006; 2: e73.Enterlein S., Warfield K.L., Swenson D.L., Stein D.A., Smith J.L., Gamble C.S., Kroe A.D., Iversen P.L., Bavari S., Muhlberger E. VP 35 knockdown inhibits Ebola virus amplification and protects against a lethal infection in mice. Antimicrob. Agents Chemother. 2006; 50:984-93.Enterlein S., Warfield K.L., Swenson D.L., Stein D.A., Smith J.L., Gamble C.S., Kroe A.D., Iversen P.L., Bavari S., Muhlberger E. VP 35 knockdown inhibits Ebola virus amplification and protects against a lethal infection in mice. Antimicrob. Agents Chemother. 2006; 50:984–93.Feldmann H., Geisbert T.W. Ebola hemorrhagic fever. Lancet. 2011; 377:849-62.Feldmann H., Geisbert T.W. Ebola hemorrhagic fever. Lancet. 2011; 377:849–62.Geisbert T.W., Hensley L.E., Kagan E. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 2006; 193(12):1650-7.Geisbert T.W., Hensley L.E., Kagan E. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 2006; 193(12):1650–7.Geisbert T.W., Larsen T., Geisbert J.B., Paragas J., Young H.A., Frederic T.M., Rote W.E., Vlasuk G.P., Joffe S. Evaluation novel therapies during the Ebola epidemic. Available from: http:// jamanetwork.com/on 28/09/2014 (дата обращения 28.09.2014).Geisbert T.W., Larsen T., Geisbert J.B., Paragas J., Young H.A., Frederic T.M., Rote W.E., Vlasuk G.P., Joffe S. Evaluation novel therapies during the Ebola epidemic. [cited 28 Sep 2014]. Available from: http://jamanetwork.com/on 28/09/2014.Geisbert T.W., Lee A.C.H., Robbins M., Honko A.N., Sood V., Johnson J.C., Jong S., Tavakoli I., Judge A., Hensley L.E., MacLahlan I. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010; 375:1896-905.Geisbert T.W., Lee A.C.H., Robbins M., Honko A.N., Sood V., Johnson J.C., Jong S., Tavakoli I., Judge A., Hensley L.E., MacLahlan I. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010; 375:1896–905.Heald A.E., Iversen P.L., Saoud J.B., Sazani P., Charleston J.S., Axtelle T., Wong M., Smith W.B., Vutikullird A., Kaye E. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg Virus: results of two single ascending dose studies. Available from: http/aac.asm.org/content/58/11/6639.abstract (дата обращения 22.03.2014).Heald A.E., Iversen P.L., Saoud J.B., Sazani P., Charleston J.S., Axtelle T., Wong M., Smith W.B., Vutikullird A., Kaye E. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg Virus: results of two single ascending dose studies. [cited 22 Mar 2014]. Available from: http/aac.asm.org/content/58/11/6639.abstract.Hensley L.E., Stewens E.L., Yan S.B., Geisbert J.B., Macias W.L., Larsen T., Cassel G.H., Jahrling P.B., Geisbert T.W. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 2007; 196:390-9.Hensley L.E., Stewens E.L., Yan S.B., Geisbert J.B., Macias W.L., Larsen T., Cassel G.H., Jahrling P.B., Geisbert T.W. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 2007; 196:390–9.Hornung V., Guenthner-Biller M., Bourguin С., Ablasser A., Sohlee M., Uemasn S., Noronha A., Manoharan M., Akira S., de Fongerolles A., Endres S., Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 2005; 11:263-70.Hornung V., Guenthner-Biller M., Bourguin С., Ablasser A., Sohlee M., Uemasn S., Noronha A., Manoharan M., Akira S., de Fongerolles A., Endres S., Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 2005; 11:263–70.Iversen P.L., Warren T.K., Wells J.B., Garza N.L., Mourich D.V., Welch L.S., Panchal R.G., Bavari S. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infection. Viruses. 2012; 4:2806-30.Iversen P.L., Warren T.K., Wells J.B., Garza N.L., Mourich D.V., Welch L.S., Panchal R.G., Bavari S. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infection. Viruses. 2012; 4:2806–30.Jahrling P.B., Geisbert J.B., Swearingen J.R., Larsen T., Geisbert T.W. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 2007; 196:400-3.Jahrling P.B., Geisbert J.B., Swearingen J.R., Larsen T., Geisbert T.W. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 2007; 196:400–3.Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., McLachian I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 2005; 23:457-62.Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., McLachian I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 2005; 23:457–62.Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siРНК therapeutics. Nature materials. 2013; 12:967-77. doi:10.1038/nmat3765.Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siРНК therapeutics. Nature materials. 2013; 12:967–77. doi:10.1038/nmat3765.Kim D.H., Rossi J.J. Strategies for silencing disease using RNA interference. Nat. Rev. Genet. 2007; 8:173-84.Kim D.H., Rossi J.J. Strategies for silencing disease using RNA interference. Nat. Rev. Genet. 2007; 8:173–84.Maruyama T. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 1999; 73:6024-30.Maruyama T. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 1999; 73:6024–30.Prins K.S., Delpeut S., Leung D.W., Reunard O., Volebkova V.A., Reid S.P., Ramanan P., Cardenas W.B., Amarasinghe G.K., Volchov V.E., Basler C.F. Mutations abrogating VP 35 interaction with double stranded RNA render Ebola virus avirulent in guinea pigs. J. Virol. 2010; 84:3004-15.Prins K.S., Delpeut S., Leung D.W., Reunard O., Volebkova V.A., Reid S.P., Ramanan P., Cardenas W.B., Amarasinghe G.K., Volchov V.E., Basler C.F. Mutations abrogating VP 35 interaction with double stranded RNA render Ebola virus avirulent in guinea pigs. J. Virol. 2010; 84:3004–15.Qiu X., Wong G., Audet J., Bello A., Fernando L., Alimonti J.B., Fausther-Bovendo H., Aviles J., Hiatt E., Johnson A., Morton J., Swope K., Bohorov O., Bohorova N., Goodman C., Kim D., Pauly M.H., Velasci J., Pettit J., Olinger G.G., Whaley K., Xu B., Strong J.E., Zetlin L., Kobinger G.P. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514(7520):47-53.Qiu X., Wong G., Audet J., Bello A., Fernando L., Alimonti J.B., Fausther-Bovendo H., Aviles J., Hiatt E., Johnson A., Morton J., Swope K., Bohorov O., Bohorova N., Goodman C., Kim D., Pauly M.H., Velasci J., Pettit J., Olinger G.G., Whaley K., Xu B., Strong J.E., Zetlin L., Kobinger G.P. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514(7520):47–53.Reid S.P., Leung D.W., Hartman A.L., Martinez O., Shaw M.L., Carbonnelle C., Volchov V.E., Nichol S.T., Basler C.F. Ebola virus VP24 binds karyopherin alpha 1 and blocks STATi nuclear accumulation. J. Virol. 2006; 80:5156-67.Reid S.P., Leung D.W., Hartman A.L., Martinez O., Shaw M.L., Carbonnelle C., Volchov V.E., Nichol S.T., Basler C.F. Ebola virus VP24 binds karyopherin alpha 1 and blocks STATi nuclear accumulation. J. Virol. 2006; 80:5156–67.Robbins M., Judge A., Ambegia E., Choi C., Yaworski E., Palmer L., McClintock K., Mac Lachlan I. Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum. Gene Ther. 2008; 19:991-9.Robbins M., Judge A., Ambegia E., Choi C., Yaworski E., Palmer L., McClintock K., Mac Lachlan I. Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum. Gene Ther. 2008; 19:991–9.Tam Y.C., Chen S., Cullis P.R. Advances in lipid nanoparticles for siРНК delivery. Pharmaceutics. 2013; 5: 498-507.Tam Y.C., Chen S., Cullis P.R. Advances in lipid nanoparticles for siРНК delivery. Pharmaceutics. 2013; 5: 498–507.Torrecila J., Rodriguez-Gascon A., Solinis M.A., del Pozo-Rodriguez A. Lipid nanoparticles as carriers for RNAi against viral infections current status and future perspectives. Biomed Res. Int. 2014; 2014:161794. doi: 10.1155/2014/161794.Torrecila J., Rodriguez-Gascon A., Solinis M.A., del Pozo-Rodriguez A. Lipid nanoparticles as carriers for RNAi against viral infections current status and future perspectives. Biomed Res. Int. 2014; 2014:161794. doi: 10.1155/2014/161794.Volchov V.E., Chepurnov A.A., Volchova V.A., Ternovoj V.A., Klenk H.D. Molecular characterization guinea pig-adapted variants of Ebola virus. Virology. 2000; 277:147-55.Volchov V.E., Chepurnov A.A., Volchova V.A., Ternovoj V.A., Klenk H.D. Molecular characterization guinea pig-adapted variants of Ebola virus. Virology. 2000; 277:147–55.Warfield K.L., Swenson D.L., Olinger G.G., Olinger G.G., Nichols D.K., Pratt W.D., Blonch R., Stein D.A., Aman M.J., Iversen P.L., Bavari S. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006; 2:e1.Warfield K.L., Swenson D.L., Olinger G.G., Olinger G.G., Nichols D.K., Pratt W.D., Blonch R., Stein D.A., Aman M.J., Iversen P.L., Bavari S. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006; 2:e1.Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 2009; 8:129-38.Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 2009; 8:129–38.Zhang YunFang, Li DaPeng, Jin Xia, Huang Zhong. Fighting Ebola with ZMapp: spotlight on plant-made antibody. Science China Life Sciences. 2014; 57(10):987-8.Zhang YunFang, Li DaPeng, Jin Xia, Huang Zhong. Fighting Ebola with ZMapp: spotlight on plant-made antibody. Science China Life Sciences. 2014; 57(10):987–8.

The authors declare that there are no conflicts of interest present.